US Price Negotiation Hearing Lays The Groundwork For Future Improvements

The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.

Capitol with medicine icons
• Source: Shutterstock

A proposal to equalize the commercial lifespan of small molecules and biologics at 13 years before becoming subject to Medicare price negotiation received the most attention among industry-suggested fixes to the Inflation Reduction Act price reform law during a House Energy & Commerce Oversight hearing last month.

Key Takeaways

  • The September hearing marks the formal beginning of the legislative effort to reform or repeal the Medicare price setting program.

The IRA sets a shorter timeline (nine years) before small molecules are subject to price cuts under the law –...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access